Co-Authors
This is a "connection" page, showing publications co-authored by MURALI CHINTAGUMPALA and SUSAN LYNNE MCGOVERN.
Connection Strength
1.813
-
The role of surgery in recurrent ependymomas. J Neurosurg Pediatr. 2023 11 01; 32(5):584-589.
Score: 0.228
-
Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience. J Neurooncol. 2023 Jul; 163(3):717-726.
Score: 0.226
-
Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma. Cancer. 2021 Oct 15; 127(20):3865-3871.
Score: 0.197
-
Early radiotherapy preserves vision in sporadic optic pathway glioma. Cancer. 2021 07 01; 127(13):2358-2367.
Score: 0.193
-
Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol. 2019 05 06; 21(5):686-695.
Score: 0.169
-
Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy. Radiother Oncol. 2018 07; 128(1):128-132.
Score: 0.155
-
Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. Int J Radiat Oncol Biol Phys. 2014 Dec 01; 90(5):1143-52.
Score: 0.123
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
Score: 0.062
-
Late-onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma. Pediatr Blood Cancer. 2024 Jul; 71(7):e31022.
Score: 0.060
-
Comparison of neurocognitive and quality-of-life outcomes in pediatric craniopharyngioma patients treated with partial resection and radiotherapy versus gross-total resection only. J Neurosurg Pediatr. 2023 05 01; 31(5):453-462.
Score: 0.055
-
Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors. Neuro Oncol. 2022 09 01; 24(9):1571-1581.
Score: 0.053
-
Observed-to-expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma: A Surveillance, Epidemiology, and End Results analysis. Cancer. 2021 07 01; 127(13):2368-2375.
Score: 0.048
-
Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):718-725.
Score: 0.048
-
Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis. Pediatr Blood Cancer. 2020 08; 67(8):e28373.
Score: 0.046
-
Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma. Pediatr Blood Cancer. 2019 11; 66(11):e27952.
Score: 0.043
-
Patterns of failure following proton beam therapy for head and neck rhabdomyosarcoma. Radiother Oncol. 2019 05; 134:143-150.
Score: 0.042
-
Outcomes for pediatric patients with central nervous system germ cell tumors treated with proton therapy. Clin Transl Radiat Oncol. 2016 Dec; 1:9-14.
Score: 0.035
-
Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys. 2014 Oct 01; 90(2):354-61.
Score: 0.030